Microbiome-Metabolome Crosstalk as a Driver of COVID-19 Severity.

Severe COVID-19 was associated with reduced microbial diversity compared to mild cases.

• Study used a prospective cohort of 55 patients with stool and plasma samples analyzed using 16S rRNA sequencing and untargeted LC-HRMS metabolomics.
• Reduced microbial diversity was a distinguishing feature of severe COVID-19 cases.
• Both stool and plasma samples were collected to assess microbiome-metabolome relationships.

Severe COVID-19 cases showed enrichment of pro-inflammatory microbial taxa including Prevotella, Alistipes, Dialister, and Lachnoclostridium.

• These taxa were identified as enriched specifically in severe disease using 16S rRNA sequencing.
• In contrast, mild cases showed higher abundance of protective commensals such as Bacteroides, Faecalibacterium, and Blautia.
• The differential microbial composition was identified in a cohort of 55 COVID-19 patients.

Metabolomic profiling revealed alterations in bile acids, unsaturated fatty acids, tryptophan, and inositol phosphate pathways in COVID-19 patients.

• Untargeted LC-HRMS metabolomics was used to profile plasma metabolites.
• Pathway alterations were identified across multiple metabolic categories including bile acids, unsaturated fatty acids, tryptophan, and inositol phosphate pathways.
• These metabolic disruptions were associated with varying levels of COVID-19 severity.

Linoleate levels were elevated in severe COVID-19 cases and showed correlations with pro-inflammatory microbes.

• Linoleate is an unsaturated fatty acid identified as significantly altered in severe disease.
• Elevated linoleate levels correlated with the pro-inflammatory microbial taxa enriched in severe cases.
• This finding was identified through integrated microbiome-metabolome analysis.

Acylcarnitines and inositol derivatives were enriched in mild COVID-19 disease.

• These metabolites were identified as potentially protective or associated with less severe disease outcomes.
• Acylcarnitines and inositol derivatives were identified through untargeted LC-HRMS plasma metabolomics.
• Their enrichment in mild cases contrasted with the linoleate elevation seen in severe cases.

Predictive functional analysis indicated that severe-associated microbes showed enhanced amino acid catabolism, oxidative glucose metabolism, and xenobiotic degradation.

• These predicted functional pathways in severe-associated microbes may be linked to host inflammation.
• Functional prediction was performed as part of the microbiome analysis pipeline.
• These metabolic functions of the microbiota were proposed as potential contributors to immune dysregulation in severe disease.

Traditional risk factors incompletely explain the heterogeneity in COVID-19 severity, highlighting the potential role of gut microbiota and host metabolomics.

• COVID-19 severity ranges from mild symptoms to respiratory failure and multiorgan dysfunction.
• The study was motivated by the inability of traditional risk factors to fully account for disease severity variability.
• Gut microbiota and host metabolomics were investigated as modulators of immune responses.

Identified microbial and metabolomic signatures may represent potential biomarkers and therapeutic targets to modulate COVID-19 disease progression.

• The study identified both microbial taxa and circulating metabolites as candidate biomarkers.
• These signatures could potentially be targeted therapeutically to alter disease course.
• The findings were derived from a prospective cohort of 55 patients using combined 16S rRNA sequencing and LC-HRMS metabolomics.